US Bancorp DE Has $580,000 Stake in Perspecta Inc (NASDAQ:PRSP)

Share on StockTwits

US Bancorp DE decreased its position in Perspecta Inc (NASDAQ:PRSP) by 6.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 28,718 shares of the company’s stock after selling 2,064 shares during the period. US Bancorp DE’s holdings in Perspecta were worth $580,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PRSP. New York State Common Retirement Fund lifted its stake in Perspecta by 3.4% in the 1st quarter. New York State Common Retirement Fund now owns 145,800 shares of the company’s stock valued at $2,948,000 after buying an additional 4,800 shares in the last quarter. Laurion Capital Management LP increased its holdings in shares of Perspecta by 229.5% during the 1st quarter. Laurion Capital Management LP now owns 54,518 shares of the company’s stock worth $1,102,000 after buying an additional 37,971 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Perspecta by 81.0% during the 1st quarter. JPMorgan Chase & Co. now owns 1,666,248 shares of the company’s stock worth $33,692,000 after buying an additional 745,898 shares during the last quarter. Mason Street Advisors LLC increased its holdings in Perspecta by 0.9% in the 1st quarter. Mason Street Advisors LLC now owns 74,785 shares of the company’s stock valued at $1,512,000 after purchasing an additional 698 shares during the last quarter. Finally, Water Island Capital LLC acquired a new stake in Perspecta in the 1st quarter valued at approximately $3,067,000.

Shares of Perspecta stock traded up $0.15 during trading hours on Wednesday, hitting $23.16. The company’s stock had a trading volume of 19,926 shares, compared to its average volume of 803,155. Perspecta Inc has a 1-year low of $15.74 and a 1-year high of $26.64.

Perspecta (NASDAQ:PRSP) last posted its quarterly earnings data on Thursday, June 6th. The company reported $0.54 EPS for the quarter, beating the Zacks’ consensus estimate of $0.48 by $0.06. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter last year, the company earned $0.47 earnings per share. The company’s revenue was up 53.0% compared to the same quarter last year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 16th. Investors of record on Wednesday, June 5th will be given a $0.06 dividend. The ex-dividend date of this dividend is Tuesday, June 4th. This is an increase from Perspecta’s previous quarterly dividend of $0.05. This represents a $0.24 annualized dividend and a yield of 1.04%.

Several research firms have commented on PRSP. Goldman Sachs Group began coverage on shares of Perspecta in a research note on Thursday, May 9th. They issued a “sell” rating and a $21.00 price target for the company. Zacks Investment Research raised shares of Perspecta from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research report on Wednesday. Cowen cut shares of Perspecta from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $28.00 to $26.00 in a research report on Monday. Loop Capital lifted their price objective on shares of Perspecta to $22.00 and gave the company a “hold” rating in a research note on Friday, June 7th. Finally, Morgan Stanley started coverage on shares of Perspecta in a research note on Monday, June 3rd. They set an “underweight” rating and a $20.00 price target on the stock. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $24.86.

In other news, CEO John M. Curtis bought 9,578 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were acquired at an average cost of $20.76 per share, with a total value of $198,839.28. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO John Kavanaugh bought 2,398 shares of the company’s stock in a transaction dated Thursday, March 21st. The stock was purchased at an average cost of $21.08 per share, for a total transaction of $50,549.84. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 25,675 shares of company stock worth $551,677.

TRADEMARK VIOLATION NOTICE: This article was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/4369485/us-bancorp-de-has-580000-stake-in-perspecta-inc-nasdaqprsp.html.

Perspecta Company Profile

There is no company description available for Perspecta Inc

Featured Article: What are the qualifications of a portfolio manager?

Want to see what other hedge funds are holding PRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perspecta Inc (NASDAQ:PRSP).

Institutional Ownership by Quarter for Perspecta (NASDAQ:PRSP)

Receive News & Ratings for Perspecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspecta and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Fluz Fluz  Price Hits $0.0319 on Major Exchanges
Fluz Fluz Price Hits $0.0319 on Major Exchanges
$0.97 EPS Expected for Sonoco Products Co  This Quarter
$0.97 EPS Expected for Sonoco Products Co This Quarter
X-CASH Price Hits $0.0000 on Top Exchanges
X-CASH Price Hits $0.0000 on Top Exchanges
InfuSystem Holdings Inc  Short Interest Up 54.3% in May
InfuSystem Holdings Inc Short Interest Up 54.3% in May
Zacks: Harrow Health  Receives Consensus Rating of “Strong Buy” from Analysts
Zacks: Harrow Health Receives Consensus Rating of “Strong Buy” from Analysts
Jefferies Financial Group Analysts Give Grand City Properties  a €20.00 Price Target
Jefferies Financial Group Analysts Give Grand City Properties a €20.00 Price Target


© 2006-2019 Ticker Report